Annual report pursuant to Section 13 and 15(d)

Consolidated Statements of Operations and Comprehensive Loss

v3.21.2
Consolidated Statements of Operations and Comprehensive Loss - USD ($)
shares in Thousands, $ in Thousands
 12 Months Ended
Jun. 30, 2021
Jun. 30, 2020
Consolidated Statements of Operations and Comprehensive Loss    
Revenues $ 2,371 $ 1,638
Cost of goods sold 1,462 703
Gross profit 909 935
Operating expenses:    
Research and development (related party of $0 and $97) 9,989 3,573
General and administrative (related party of $1,587 and $1,143) 22,031 11,365
Total operating expenses 32,020 14,938
Operating loss (31,111) (14,003)
Other income (expense):    
Interest income 140 15
Interest expense (related party of $2,446 and $2,466) (2,454) (2,466)
Royalty income 12 10
Settlement income 10,200  
Total other income (expense) 7,898 (2,441)
Consolidated net loss (23,213) (16,444)
Net loss attributable to noncontrolling interest 6 5
Net loss attributable to iBio, Inc. (23,207) (16,439)
Deemed dividends – down round of Series A Preferred and Series B Preferred   (21,560)
Preferred stock dividends – iBio CMO Tracking Stock (260) (261)
Net loss attributable to iBio, Inc. stockholders (23,467) (38,260)
Comprehensive loss:    
Consolidated net loss (23,213) (16,444)
Other comprehensive loss - unrealized loss on debt securities (29)  
Other comprehensive loss - foreign currency translation adjustments (1) (2)
Comprehensive loss $ (23,243) $ (16,446)
Loss per common share attributable to iBio, Inc. stockholders - basic and diluted $ (0.12) $ (0.61)
Weighted-average common shares outstanding - basic and diluted 195,620 62,795